United states: In a significant development for Alzheimer’s care, the United States Food and Drug Administration (FDA) has approved the first at-home self-injection treatment for patients with early Alzheimer’s disease. The approval allows eligible patients or their caregivers to administer the medication at home using an autoinjector, reducing the need for frequent hospital or clinic visits for intravenous (IV) infusions.

The approval was granted to Eisai and Biogen’s supplemental Biologics License Application (sBLA) for LEQEMBI IQLIK (lecanemab-irmb), a once-weekly subcutaneous injection designed for the treatment of adults diagnosed with early Alzheimer’s disease.

The companies announced that the new formulation is expected to become available across the United States by late August 2026 through specialty pharmacies.

The approval marks another milestone in Alzheimer’s treatment, offering patients greater flexibility while maintaining access to disease-modifying therapy.

What is LEQEMBI IQLIK?

LEQEMBI IQLIK is a subcutaneous version of the Alzheimer’s drug lecanemab-irmb, which was previously administered primarily through intravenous infusions in hospitals or infusion centres.

The newly approved formulation enables patients or caregivers to administer the medicine at home using an autoinjector.

For treatment initiation, patients receive a 500 mg weekly dose, administered as two 250 mg injections, each taking approximately 15 seconds to deliver.

After completing 18 months of IV or subcutaneous therapy, eligible patients may transition to a 360 mg weekly maintenance dose.

Throughout the treatment period, patients can continue using either intravenous infusions or the newly approved subcutaneous injection, depending on medical advice and individual circumstances.

Who can receive the treatment?

LEQEMBI IQLIK is approved for adults with early Alzheimer’s disease, including patients diagnosed with:

  • Mild cognitive impairment (MCI) due to Alzheimer’s disease
  • Mild Alzheimer’s dementia

Mild cognitive impairment is often considered one of the earliest stages of Alzheimer’s disease. Symptoms may include increasing forgetfulness, difficulty finding words, confusion, reduced concentration and other subtle memory-related changes that interfere with daily life.

Doctors typically recommend treatment during these early stages, when disease-modifying therapies are expected to offer the greatest potential benefit.

How does the new injection help?

Until now, patients receiving lecanemab generally had to visit healthcare facilities regularly for intravenous infusions.

The new autoinjector offers several potential advantages:

  • Greater convenience for patients and caregivers
  • Reduced need for hospital or infusion centre visits
  • Easier long-term treatment management
  • Improved access for patients living far from specialised treatment centres
  • Greater flexibility in choosing between IV infusion and self-injection

Healthcare providers will continue to determine whether home administration is suitable for individual patients based on their medical condition and treatment response.

Experts welcome the approval

Commenting on the FDA’s decision, Dr Howard Fillit, Co-Founder and Chief Science Officer Emeritus of the Alzheimer’s Drug Discovery Foundation (ADDF), described the approval as a major advancement in Alzheimer’s care.

According to Fillit, the approval provides patients and caregivers with meaningful choice in how anti-amyloid therapy is delivered.

He also noted that innovations in drug delivery could improve access to treatment, support future combination therapies and contribute to more personalised approaches to Alzheimer’s care.

Availability

Eisai and Biogen said LEQEMBI IQLIK is expected to become commercially available in the United States by late August 2026.

Patients will be able to obtain the medication through designated specialty pharmacies after receiving a prescription from their healthcare provider.

Growing focus on Alzheimer’s therapies

Alzheimer’s disease remains one of the leading causes of dementia worldwide, affecting millions of people and placing a significant burden on patients, families and healthcare systems.

Recent advances in disease-modifying therapies have shifted attention towards slowing disease progression rather than only managing symptoms. The approval of a self-administered treatment represents another step towards making these therapies more accessible and convenient for eligible patients.

While LEQEMBI IQLIK is not a cure for Alzheimer’s disease, its approval expands treatment options for patients diagnosed during the early stages, potentially helping improve quality of life through easier access to ongoing therapy.